PSEN1 Mutations in Alzheimer's Disease

PSEN1 Mutations in Alzheimer's Disease

Overview

Psen1 Mutations In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Psen1 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@generation]

[Presenilin 1](/entities/psen1) (PSEN1) is the most common cause of autosomal dominant familial Alzheimer's disease, with over 200 pathogenic mutations identified. PSEN1 encodes the catalytic subunit of [γ-secretase](/entities/gamma-secretase), and mutations alter [amyloid-beta](/proteins/amyloid-beta) production. [@molecular]

Genetic Background

• Gene: PSEN1 (Presenilin 1)
• Chromosome: 14q24.3
• Mutations: >200 pathogenic variants identified
• Inheritance: Autosomal dominant
• Prevalence: ~30-50% of all familial AD cases

Pathophysiology

Normal Function

Presenilin 1 is the catalytic core of γ-secretase:

• Proteolytic cleavage: Cuts [APP](/entities/app-protein) at multiple sites within the transmembrane domain
• [Aβ](/proteins/amyloid-beta) generation: Produces Aβ40 (∼90%) and Aβ42 (∼10%)
• Notch signaling: Essential for Notch receptor cleavage

...

PSEN1 Mutations in Alzheimer's Disease

Overview

Psen1 Mutations In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Psen1 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@generation]

[Presenilin 1](/entities/psen1) (PSEN1) is the most common cause of autosomal dominant familial Alzheimer's disease, with over 200 pathogenic mutations identified. PSEN1 encodes the catalytic subunit of [γ-secretase](/entities/gamma-secretase), and mutations alter [amyloid-beta](/proteins/amyloid-beta) production. [@molecular]

Genetic Background

• Gene: PSEN1 (Presenilin 1)
• Chromosome: 14q24.3
• Mutations: >200 pathogenic variants identified
• Inheritance: Autosomal dominant
• Prevalence: ~30-50% of all familial AD cases

Pathophysiology

Normal Function

Presenilin 1 is the catalytic core of γ-secretase:

• Proteolytic cleavage: Cuts [APP](/entities/app-protein) at multiple sites within the transmembrane domain
• [Aβ](/proteins/amyloid-beta) generation: Produces Aβ40 (∼90%) and Aβ42 (∼10%)
• Notch signaling: Essential for Notch receptor cleavage

Mutation Effects

• Aβ42/Aβ40 ratio: Most PSEN1 mutations increase the Aβ42/Aβ40 ratio
• Total Aβ: Some mutations increase, others decrease production
• Aβ42: More aggregation-prone, forms seeds more readily

Mechanisms of Pathogenesis

γ-secretase dysfunction: Altered cleavage specificity

Aβ42 elevation: Increases amyloid nucleation

Calcium dysregulation: ER calcium homeostasis disrupted

Protein folding stress: Loss of presenilin function

[Tau](/proteins/tau) pathology: Enhanced phosphorylation and aggregation

Common Mutations

Highly Penetrant Mutations

| Mutation | Age of Onset | Aβ Effect |
|----------|--------------|-----------|
| M146L | ~45 years | Aβ42 ↑ |
| L286V | ~50 years | Aβ42 ↑↑ |
| A246E | ~50 years | Aβ42 ↑ |
| H163R | ~55 years | Aβ42 ↑ |
| A431V | ~55 years | Aβ42 ↑ |

Early-Onset Mutations (< 45 years)

• PSEN1 M146L
• PSEN1 L250S
• PSEN1 P264L

Clinical Features

Age of Onset

• Range: 30-70 years (most commonly 45-55)
• Anticipation: Earlier onset in subsequent generations (anticipation)

Phenotype

• Memory impairment: Prominent early feature
• Progression: Often rapid once symptoms begin
• Behavioral changes: Early personality changes
• Myoclonus: Common in early-onset cases
• Seizures: More frequent than late-onset AD

Neuropathology

• Amyloid plaques: Abundant Aβ42 deposition
• Neurofibrillary tangles: Severe tau pathology
• Cerebral amyloid angiopathy: Present in some mutations
• Neuronal loss: [Hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)

Genetic Testing

Indications

• Early-onset AD (< 60 years)
• Autosomal dominant family history
• Atypical presentations

Interpretation

• Pathogenic mutations: Confirm diagnosis, inform family
• Variants of uncertain significance: Require careful interpretation
• Penetrance: Near 100% by age 80

Therapeutic Implications

Targeted Approaches

γ-secretase modulators: Shift cleavage away from Aβ42

Aβ42 antibodies: May be particularly effective

Anti-aggregation drugs: Target toxic Aβ species

Clinical Trials

• PSEN1 mutation carriers often included in prevention trials
• DIAN-TU: [Dominantly Inherited Alzheimer Network](/entities/dian-study) Trials
• API: Alzheimer's Prevention Initiative
• [PSEN1 Gene](/Genes/PSEN1)
• [Proteins/Presenilin-1 Protein](/proteins/presenilin-1)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [PSEN2](/entities/psen2) Mutations in AD

Overview

Psen1 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Psen1 Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Comprehensive methodology for sample enrichment in EEG biomarker studies for Alzheimer's risk classification.](https://pubmed.ncbi.nlm.nih.gov/41811929/) (2026) - PloS one
• [Generation of a human induced pluripotent stem cell line (FLENIi004-A) from an Autosomal-Dominant Alzheimer's disease PSEN1 p.M146L patient.](https://pubmed.ncbi.nlm.nih.gov/41819741/) (2026 Mar 6) - Stem cell research
• [Molecular Complexities of Dementia: PAISA Mutations and Targeting TAF2N as Therapeutic Avenues.](https://pubmed.ncbi.nlm.nih.gov/41820211/) (2026 Mar 3) - Current gene therapy
• [Multimodal PET/MR Imaging in Early-onset Alzheimer's Disease With Parkinsonism due to a Novel Presenilin-1 (M233I) Mutation.](https://pubmed.ncbi.nlm.nih.gov/41363940/) (2026 Mar 1) - Clinical nuclear medicine
• [Alzheimer's disease basics: we all should know.](https://pubmed.ncbi.nlm.nih.gov/40639927/) (2026 Mar) - Neurological research

References